Content area

|
|

Effekten af statiner på eksacerbationer og dødelighed ved KOL

Forfatter(e)

Mathias Damkjær1, Kjell E.J. Håkansson1, Charlotte S. Ulrik1, 2 & Nina S. Godtfredsen1, 2

1) Lungemedicinsk Afdeling, Hvidovre Hospital, 2) Institut for Klinisk Medicin, Københavns Universitet

Ugeskr Læger 2020;182:V10190592

Reference: 
UgeskrLæger 2020;182:V10190592
Statins and COPD: relationship with inflammation, exacerbations and mortality

Mathias Damkjær, Kjell E.J. Håkansson, Charlotte S. Ulrik & Nina S. Godtfredsen:

Ugeskr Læger 2020;182:V10190592

The role of statins on the disease course of COPD is controversial. Observational studies have shown a reduction in mortality and exacerbations, but results of randomised clinical trials (RCTs) of statin treatment and its effect on adverse outcomes are conflicting. Recent meta-analyses suggest the need for further RCTs including COPD patients both with and without concurrent cardiovascular disease (CVD). As there are no known detrimental effects of statins in COPD patients, we conclude in this review, that statins should be prescribed more frequently in these patients due to the common co-morbidity with CVD.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Holger Ahler M. Therkildsen | 29/09
1 Kommentar
af Mats Lindberg | 29/09
1 Kommentar
af Anne Amalie Elgaard Thorup | 28/09
1 Kommentar
af Henrik Harboe | 28/09
1 Kommentar
af Svend Nielsen | 27/09
4 kommentarer
af Nini Katja Møller | 26/09
1 Kommentar
af Niels Rud Haagensen | 25/09
10 kommentarer